Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of unknown etiology and
pathogenic mechanisms. From an etiopathogenic point of view, alveolar macrophages play …

Background: The prognosis of idiopathic pulmonary fibrosis (IPF/UIP) is poor and its
immunopathogenesis is insufficiently understood. Objectives: The aim of our study was to …

Idiopathic pulmonary fibrosis (IPF) is a disease with progressive and devastating
deterioration of lung function and a fatal prognosis, despite aggressive therapeutic attempts …

Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive disease with inadequate
response to conventional treatment with corticosteroids and/or immunosuppressive agents …

PURPOSE: To evaluate how a novel treatment for idiopathic pulmonary fibrosis (IPF)
changes the cytokine profile in the bronchoalveolar lavage (BAL) fluid of IPF patients after …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease characterised by
fibroblast proliferation and extracellular matrix remodelling. The usual treatment strategy is …

Idiopathic pulmonary fibrosis (IPF) is a condition that has a poor prognosis, with a median
survival of 4-5 years irrespective of treatment. Ziesche et al (N Engl J Med 1999, 341: 1264 …

Objective: To examine the clinical aspects of idiopathic pulmonary fibrosis (IPF) and the
efficacy and safety of interferon gamma-1b (IFNγ− 1b) in its treatment. Data Sources …

In a recent study of IFN-γ 1b in 330 patients with idiopathic pulmonary fibrosis (IPF),
progression-free survival was unchanged; however, a trend toward lower mortality was seen …

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disorder. Cytokines
contribute an important but yet undefined role to its pathogenesis. OBJECTIVES: The …